Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, August 18, 2020 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") hereby announces that it has appointed Mr. Keith Alexander as new Chief Financial Officer (CFO). Mr. Alexander brings more than 20 years of corporate banking and strategy consulting experience and will initially be focused on strengthening the Company's financial strategies and investor relations function. Mr. Alexander will begin his employment on October 1, 2020 and be based out of ExpreS2ion's headquarters in Hørsholm, Denmark. The appointment of Mr. Alexander follows the strategy transformation announced earlier this year.
Mr. Alexander (44) joins ExpreS[2]ion with over 20 years of experience in investment markets, investor communications, corporate strategy and business development. He joins ExpreS[2]ion from Danske Bank Asset Management, where he was responsible for the Fixed Income & Credit Advisory & Product Specialist function. He has held previous positions at Danske Capital as Head of North America, and at J.P. Morgan in New York City as Vice President, Strategy & Business Development, and Vice President, Equity Research. He has an MBA from The Wharton School of the University of Pennsylvania in Philadelphia, PA, USA, and a B.Sc. in Industrial Management with a minor in Biological Sciences from Purdue University in West Lafayette, Indiana, USA.
ExpreS[2]ion's CEO Bent Frandsen comments:
"I am very pleased that Keith has decided to join the next stage of ExpreS[2]ions journey. His experience will be a great asset as we move forward with the strategy transformation we announced in the beginning of 2020. The first order of business is to support with financial aspects in ExpreS[2]ion's transformation to a pipeline-driven business model, including all the requirements needed to be ready to exercise our option on AV001."
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se